Individualizing pain therapy with opioids: The rational approach based on pharmacogenetics and pharmacokinetics

European Journal of Pain Supplements

Volumn 4, Issue 4, 2010, Pages 245-250

  De Gregori, Manuela ^a,b   De Gregori, Simona ^a   Ranzani, Guglielmina N ^b   Allegri, Massimo ^a   Govoni, Stefano ^b   Regazzi, Mario ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Opioids; Pain; Pharmacogenetics; Pharmacokinetics; Tandem mass spectrometry

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; FENTANYL; MORPHINE; OPIATE; OXYCODONE;

ANALYTIC METHOD; ARTICLE; CANCER PAIN; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM CARE; MASS SPECTROMETRY; NAUSEA AND VOMITING; PAIN; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RESPIRATION DEPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY;

EID: 78149357938     PISSN: 17543207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eujps.2010.09.011     Document Type: Article

References (45)

1. Apolone G., Corli O., Greco M.T., Zagonel V. CPOR SG Investigators. Factors influencing the decision to take or reject opioids for cancer pain: are we on target?. Ann Oncol 2008, 19:1021-1022.
2. Argoff C.E. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010, 26S:16-20.
3. Burmester J.K., Sedova M., Shapero M.H., Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 2010, 632:99-124.
4. Carlsson K.C., van de Schootbrugge M., Eriksen H.O., Moberg E.R., Karlsson M.O., Hoem N.O. A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. Ther Drug Monit 2009, 31:86-94.
5. Chari G., Gulati A. Bhat R and Tebbett IR High-performance liquid chromatographic determination of morphine, morphine-3-glucuronide, morphine-6- glucuronide and codeine in biological samples using multi-wavelength forward optical detection. J Chromatogr B 1991, 571:263-270.
6. Chou R. Clinical guidelines from the american pain society and the american academy of pain medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice?. Pol Arch Med Wewn 2009, 119:469-477.
7. Chou W.Y., Yang L.C., Lu H.F., Ko J.Y., Wang C.H., Lin S.H., Lee T.H., Concejero A., Hsu C.J. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006, 50:787-792.
8. Chou W.Y., Wang C.H., Liu P.H., Liu C.C., Tseng C.C., Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006, 105:334-337.
9. Comerford Dee. Techniques of opioid administration. Anaesthesia &intensive care medicine 2005, 6:16-20.
10. De Conno F., Ripamonti C., Sbanotto A., Barletta L., Zecca E., Martini C., Ventafridda V.A. Clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine and pentazocine in cancer pain. J Pain Symptom Manage 1991, 16:423-427.
11. Curtis G.B., Johnson G.H., Clark P., Taylor R., Brown J., O'Callaghan R., Shi M. And Lacouture PG Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 1999, 55:425-429.
12. Dahlström B., Paalzow L.P. Lasma, cardiac, tissue and brain morphine concentrations in acute and chronic morphine-treated rats. J Pharm Pharmacol 1975, 27:172-175.
13. De Gregori M., Allegri M., De Gregori S., Garbin G., Tinelli C., Regazzi M., Govoni S., Ranzani G.N. How and why to screen for cyp2d6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab 2010, 11:276-282.
14. Deverka P.A., Vernon J., McLeod H.L. Economic opportunities and challenges for pharmacogenomics. Annu Rev Pharmacol Toxicol 2010, 50:423-437.
15. Edlund P.O. Determination of opiates in biological samples by glass capillary gas chromatography with electron-capture detection. J Chromatogr A 1981, 206:109-116.
16. Freiermuth M., Plasse J.C. Determination of morphine and codeine in plasma by HPLC following solid phase extraction. J Pharm Biomed Anal 1997, 15:759-764.
17. Geppetti P., Benemei S. Pain treatment with opioids: achieving the minimal effective and the minimal interacting dose. Clin Drug Investig 2009, 29S:3-16.
18. Howard S., Smith M.D. Opioid Metabolism. Mayo Clin Proc 2009, 84:613-624.
19. Johannessen S.I., Landmark C.J. Value of therapeutic drug monitoring in epilepsy. Expert Rev Neurother 2008, 8:929-939.
20. Kasai S., Hayashida M., Sora I., Ikeda K. Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:269-281.
21. Kasperavicite D., Sisodiya S.M. Epilepsy pharmacogenetics. Pharmacogenomics 2009, 10:817-836.
22. Kirvela M., Lindrgen L., Seppala T., Olkkola K.T. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996, 8:13-18.
23. Klepstad P., Rakvåg T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., Baar C., Vikan T., Krokan H.E., Skorpen F. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004, 48:1232-1239.
24. Knotkova H., Fine P.G., Portenoy R.K. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009, 38:426-439.
25. Ladd L.A., Kam P.C., Williams D.B., Wright A.W.E., Smith M.T., Mather L.E. Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. Br J Clin Pharmacol 2004, 59:524-535.
26. Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.Y., Shen D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of active metabolites. Clin Pharmacol Ther 2006, 79:461-479.
27. Lee J.W., Pederson J.E., Moravetz T.L., Dzerk A.M., Mundt A.D., Shepard K.V. Sensitive and specific radioimmunoassay for opiates using commercially available materialsI: methods for the determinations of morphine and hydromorphone. J Pharm Sci 1991, 80:284-288.
28. Lotsch J., Skarke C., Tegeder I., Geisslinger G. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 2002, 41:31-57.
29. Maltoni M. Opioids, pain, and fear. Ann Oncol 2008, 19:5-7.
30. Mercandante S., Roila F., Berretto O., Labianca R., Casilini S. DOMAIN-AIOM study group Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. Support Care Cancer 2008, 16:1203-1211.
31. Milne R.W., Nation R.L., Reynolds G.D. Somogyi AA and Van Crugten JT Improved method for the determination of morphine and its 3- and 6-glucuronide metabolites. J. Chromatogr 1991, 565:457-464.
32. Pawula M. Barrett DA and Shaw PN An improved extraction method for the HPLC determination of morphine and its metabolites in plasma. J Pharm Biomed Anal 1993, 11:401-406.
33. Pergolizzi J, Pappagallo M, Stauffer J, Gharibo C, Fortner N, de Jesus MN, Brennan MJ, Richmond C, Hussey D; The Integrated Drug Compliance Study Group (IDCSG). The Role of Urine Drug Testing for Patients on Opioid Therapy. Pain Pract 2010 [Epub ahead of print].
34. Radbruch L., Sabatowski R., Elsner F., Loick G., Kohnen N. Patients' associations with regard to analgesic drugs and their forms for application-a pilot study. Support Care Cancer 2002, 10:480-485.
35. Redmond K. Organizational barriers in opioid use. Support Care Cancer 1997, 5:451-456.
36. Reyes-Gibby C.C., Shete S., Rakvåg T., Bhat S.V., Skorpen F., Bruera E., Kaasa S., Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007, 130:25-30.
37. Rollason V., Samer C., Piguet V., Dayer P., Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008, 9:905-933.
38. Rop P.P., Grimaldi F., Burle J. De Saint Leger MN and Viala A Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr B 1994, 661:245-253.
39. Sia A.T., Lim Y., Lim E.C., Goh R.W., Law H.Y., Landau R., Teo Y.Y., Tan E.C. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008, 109:520-526.
40. Sindrup S.H., Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995, 5:335-346.
41. Smith H.S., Kirsh K.L. Documentation and potential tools in long-term opioid therapy for pain. Anesthesiol Clin 2007, 25:809-823.
42. Svensson J.O. Determination of morphine Morphine-6-glucuronide and normorphine in plasma and urine with high-performance liquid chromatography and electrochemical detection. J Chromatogr 1986, 375:174-178.
43. Venn R.F., Michalkienwicz A. Fast reliable assay for morphine and its metabolites using high-performance liquid chromatography and native fluorescence detection. J Chromatogr Biomed Appl 1990, 525:379-388.
44. Victor T.W., Alvarez N.A., Gould E. Opioid prescribing practices in chronic pain management: guidelines do not sufficiently influence clinical practice. J Pain 2009, 10:1051-1057.
45. Vissers K.C. Opioid rotation in the management of chronic pain: where is the evidence?. Pain Pract 2010, 10:85-93.